Author Correction: Autophagy inhibitors increase the susceptibility of KRAS-mutant human colorectal cancer cells to a combined treatment of 2-deoxy-D-glucose and lovastatin
| Autor: | Xiao-ming Huang, Jia-jun Huang, Jing-jing Du, Na Zhang, Ze Long, You Yang, Fang-fang Zhong, Bo-wen Zheng, Yun-fu Shen, Zhe Huang, Xiang Qin, Jun-he Chen, Qian-yu Lin, Wan-jun Lin, Wen-zhe Ma |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Pharmacology
Mice Inbred BALB C Dose-Response Relationship Drug Antimetabolites Cell Survival Correction Mice Nude Chloroquine General Medicine Deoxyglucose HCT116 Cells Xenograft Model Antitumor Assays Proto-Oncogene Proteins p21(ras) Mice HEK293 Cells Mutation Autophagy Animals Humans Pharmacology (medical) Drug Therapy Combination Female Lovastatin Hydroxymethylglutaryl-CoA Reductase Inhibitors Colorectal Neoplasms |
| Zdroj: | Acta Pharmacol Sin |
| Popis: | RAS-driven colorectal cancer relies on glucose metabolism to support uncontrolled growth. However, monotherapy with glycolysis inhibitors like 2-deoxy-D-glucose causes limited effectiveness. Recent studies suggest that anti-tumor effects of glycolysis inhibition could be improved by combination treatment with inhibitors of oxidative phosphorylation. In this study we investigated the effect of a combination of 2-deoxy-D-glucose with lovastatin (a known inhibitor of mevalonate pathway and oxidative phosphorylation) on growth of KRAS-mutant human colorectal cancer cell lines HCT116 and LoVo. A combination of lovastatin (3.75 μM) and 2-deoxy-D-glucose (1.25 mM) synergistically reduced cell viability, arrested cells in the G |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|